FDA approves first drug for obstructive sleep apnea that aids weight loss

The U.S. Food and Drug Administration (FDA) has approved Eli Lilly's Zepbound (tirzepatide) as the first medication for moderate to severe obstructive sleep apnea (OSA) in adults with obesity. This approval, announced on December 20, marks a significant development in OSA treatment. Zepbound is intended to be used alongside a reduced-calorie diet and increased physical activity. The drug works by activating hormones that reduce appetite, leading to weight loss, which can improve OSA symptoms. While Zepbound shows promise, it may cause side effects such as nausea and fatigue. The FDA advises patients to consult with their doctors before starting the medication, especially those with a history of certain thyroid conditions.